Design of Selective sPLA2-X Inhibitor (−)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid

Authors:

Abstract
A fragment-based lead generation campaign identified a series of indole-based sPLA2-X inhibitors with a promising selectivity profile against other sPLA2 isoforms. Further optimisation of sPLA2 selectivity and metabolic stability resulted in the design of (S)-23, a novel, potent and selective sPLA2-X inhibitor with an exquisite pharmacokinetic profile characterised by high absorption and low clearance, and low toxicological risk. (S)-23 was tested in an ApoE-/- murine model of atherosclerosis to evaluate the effect of reversible, pharmacological sPLA2-X inhibition on atherosclerosis development. Despite being well tolerated and achieving adequate systemic exposure of mechanistic relevance, (S)-23 did not significantly affect circulating lipid and lipoprotein biomarkers, had no effect on coronary function or histological markers of atherosclerosis.
Funding Information
  • AstraZeneca

This publication has 19 references indexed in Scilit: